A new strategy for treatment of autoimmune diseases in chimeric resistant MRL/Ipr mice

Blood

Volumn 91, Issue 12, 1998, Pages 4616-4623

  Takeuchi, Kenji ^a   Inaba, Muneo ^a   Miyashima, Shigeo ^a   Ogawa, Ryokei ^a   Ikehara, Susumu ^a  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CD3 ANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; THY 1 ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE DISEASE; BONE GRAFT; BONE MARROW TRANSPLANTATION; CELL TRANSPLANTATION; CONTROLLED STUDY; FEMALE; IMMUNOPATHOLOGY; INTRAPERITONEAL DRUG ADMINISTRATION; IRRADIATION; LYMPHADENOPATHY; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0031840228     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v91.12.4616     Document Type: Article

References (30)

1. Morse HC III, Davidson WF, Yetter RE, Murphy ED, Roths JB, Coffman R: Abnormalities induced by the mutant gene lpr: Expansion of a unique lymphocyte subset. J Immunol 129:2612, 1982
2. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S: Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356:314, 1992
3. Murphy ED, Roths JB: Autoimmunity and lymphoproliferation. Induction by mutant gene lpr, and acceleration by a male-associated factor in strain BXSB mice, in Rose NR, Bigazzi PE, Werner NL (eds): Genetic Control of Autoimmune Disease. New York, NY, Elsevier North Holland, 1978, p 207
4. Andrews BS, Eisenberg RA, Theofilopoulos AN, Izui S, Wilson CB, McConahey PJ, Murphy ED, Roths JB, Dixon FJ: Spontaneous murine lupus-like syndrome. J Exp Med 148:1198, 1978
5. Theofilopoulos AN, Dixon FJ: Murine models of systemic lupus erythematosus. Adv Immunol 37:269, 1985
6. Davidson WF, Dumont FJ, Bedigan HG, Fowlkes BJ, Morse HC III: Phenotypic, functional, and molecular genetic comparisons of the abnormal lymphoid cells of C3H-lpr/lpr and C3H-gld/gld mice. J Immunol 136:4075, 1986
7. Ishida T, Inaba M, Hisha H, Sugiura K, Adachi Y, Nagata N, Ogawa R, Good RA, Ikehara S: Requirement of donor-derived stromal cells in the bone marrow for successful allogeneic bone marrow transplantation. J Immunol 152:3119, 1994
8. Miyashima S, Nagata N, Nakagawa T, Hosaka N, Takeuchi K, Ogawa R, Ikehara S: Prevention of lpr-graft-versus host disease and transfer of autoimmune diseases in normal C57BL/6 mice by transplantation of bone marrow cells plus bones (stromal cells) from MRL/lpr mice. J Immunol 156:79, 1996
9. Ikehara S, Yasumizu R, Inaba M, Izui S, Hayakawa K, Sekita K, Toki J, Sugiura K, Iwai H, Nakamura T, Muso E, Hamashima Y, Good RA: Long-term observations of autoimmune-prone mice treated for autoimmune disease by allogeneic bone marrow transplantation. Proc Natl Acad Sci USA 86:3306, 1989
10. Wofsy D, Ledbetter JA, Hendler PL, Seaman WE: Treatment of murine lupus with monoclonal anti-T cell antibody. J Immunol 134:852, 1985
11. + T cells to lymphoproliferation and autoantibody production in MRL-lpr/ lpr mice. J Exp Med 167:1713, 1988
12. Ginzler EM, Bollet AJ, Friedman EA: The natural history and response to therapy of lupus nephritis. Annu Rev Med 31:463, 1980
13. Steinberg AD. Steinberg SC: Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with predonisone alone. Arthritis Rheum 34:945, 1991
14. Jerne NK, Nordin AA: Plaque formation in agar by single antibody-producing cells. Science 140:405, 1963
15. Izui S, Eisenberg RA: Circulating anti-DNA-rheumatiod factor complexes in MRL/1 mice. Clin Immunol Immunopathol 15:536, 1980
16. Ikehara S, Good RA, Nakamura T, Sekita K, Inoue S, Oo MM, Muso E, Ogawa K, Hamashima Y: Rationale for bone marrow transplantation in the treatment of autoimmune diseases. Proc Natl Acad Sci USA 82:2483, 1985
17. Mayumi H, Good, RA: Long-lasting skin allograft tolerance in adult mice induced across fully allogeneic (multimajor H-2 plus multiminor histocompatibility) antigen barriers by a tolerance-inducing method using cyclophosphamide. J Exp Med 169:213, 1989
18. Chu JL, Ramos P, Rosendorff A, Nikolic-Zugic J, Lacy E, Matsuzawa A, Elkon KB: Massive upregulation of the Fas ligand in lpr and gld mice: Implications for Fas regulation and the graft-versus-host disease-like wasting syndrome. J Exp Med 181:393, 1995
19. Ito MR, Terasaki S, Itoh J, Katoh H, Yonehara S, Nose M: Rheumatic diseases in an MRL strain of mice with a deficit in the functional Fas ligand. Arthritis Rheum 40:1054, 1997
20. Shin T, Himeno, K, Mayuni H, Nomoto K: Drug-induced tolerance to allografts in mice. III. Prolongation of skin graft survival by tolerance induction in congenic mice disparate in the major H-2 antigens. Transplantation 39:333, 1985
21. Mayumi H, Kayashima K, Shin T, Nomoto K: Drug-induced tolerance to allografts in mice. v. Prolongation of skin graft survival in tolerant mice with combined immunosuppressive treatment. Transplantation 39:335, 1985
22. Tomita Y, Ayukawa K, Yoshikai Y, Nomoto K: Mechanism of cyclophosphamide-induced tolerance to IE-encoded alloantigens: Evidence of clonal deletion in effector cells for skin allograft rejection. Transplantation 53:602, 1992
23. Tomita Y, Nishimura Y, Harada N, Eto M, Ayukawa K, Yoshikai Y, Nomoto K: Evidence for involvement of clonal anergy in MHC class I and class II disparate skin allograft tolerance after the termination of intrathymic clonal deletion. J Immunol 145:4026, 1990
24. Tomita Y, Nomoto K: Prevention of induction of unresponsiveness to class I antigens by veto activity of donor marrow in cyclophosphamide-treated mice. Transplantation 56:1473, 1993
25. Tomita Y, Mayumi H, Eto M, Nomoto K: Importance of suppressor T cells in cyclophosphamide-induced tolerance to the non-H-2-encoded alloantigens. J Immunol 144:463, 1990
26. Martin PJ: Donor CDS cells prevent allogeneic marrow graft rejection in mice: Potential implications for marrow transplantation in humans. J Exp Med 178:703, 1993
27. Marmont AM: Immune ablation followed by allogeneic or autologous bone marrow transplantation: A new treatment for severe autoimmune diseases? Stem Cells 12:125, 1994
28. Euler HH, Marmont AM, Bacigalupo A, Fastenrath S, Dreger P, Hoffknecht M, Zander AR, Schalke B, Hahn U, Haas R, Schmilz N: Early recurrence of persistence of autoimmune diseases after unmanipulated autologous stem cell transplantation. Blood 88:3621, 1996
29. Nelson JL, Torrez R, Louie FM, Choe OS, Storb R. Sullivan KM: Pre-existing autoimmune diseases in patients with longterm survival after allogeneic bone marrow transplantation. J Rhematol 24:23, 1997
30. Karussis DM, Vourka-Karussis U, Lehmann D, Abramsky O, Ben-Nun A, Slavin S: Immunomodulation of autoimmunity in MRL/lpr mice with syngeneic bone marrow transplantation. Clin Exp Immunol 100:111, 1995